Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 2/20 | 0.41 |
| ▸ | SKP1 | P63208 | 2/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404082 | 1.00 | PTPN11 (0.48) | PTPN11ACHEGPR119MAPTCHRNA7 | |
| SCHEMBL12269699 | 1.00 | PTPN11 (0.48) | PTPN11ACHEGPR119MAPTCHRNA7 | |
| SCHEMBL18032430 | 0.88 | PTPN11 (0.49) | PTPN11ACHEGPR119MAPTCHRNA7 | |
| SCHEMBL12269614 | 0.86 | PTPN11 (0.46) | PTPN11ACHEGPR119MAPTCHRNA7 | |
| SCHEMBL2403700 | 0.86 | PTPN11 (0.46) | PTPN11ACHEGPR119MAPTCHRNA7 | |
| SCHEMBL2403695 | 0.86 | PTPN11 (0.46) | PTPN11ACHEGPR119MAPTCHRNA7 | |
| SCHEMBL2402244 | 0.84 | ABL1 (0.37) | PTPN11TSHRSMN1; SMN2 | |
| SCHEMBL12269550 | 0.82 | CKS1B (0.41) | PTPN11ACHEGPR119MAPTCKS1B | |
| SCHEMBL16651989 | 0.79 | PTPN11 (0.53) | PTPN11ACHEGPR119MAPTCHRNA7 | |
| SCHEMBL2402135 | 0.78 | PTPN11 (0.62) | PTPN11ACHEGPR119MAPTCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545058-B1 | TETRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS INHIBITORS OF HISTAMINE RECEPTORS | KALYPSYS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8569300-B2 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease | KALYPSYS INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2545058-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | Kalypsys, Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2011112766-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237565-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | PTPN11 3809/4885ACHE 677/4885GPR119 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.